Reviewing CG Oncology (CGON) and Its Peers

CG Oncology (NASDAQ:CGON) is one of 300 public companies in the “Biological products, except diagnostic” industry, but how does it weigh in compared to its rivals? We will compare CG Oncology to related companies based on the strength of its analyst recommendations, institutional ownership, dividends, risk, profitability, earnings and valuation.

Profitability

This table compares CG Oncology and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
CG Oncology	-10,642.98%	-18.97%	-15.36%
CG Oncology Competitors	-2,185.76%	-161.46%	-40.62%

Analyst Ratings

This is a breakdown of current recommendations and price targets for CG Oncology and its rivals, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CG Oncology	0	0	9	1	3.10
CG Oncology Competitors	1927	5386	13958	296	2.59

CG Oncology presently has a consensus target price of $63.88, suggesting a potential upside of 187.21%. As a group, “Biological products, except diagnostic” companies have a potential upside of 107.03%. Given CG Oncology’s stronger consensus rating and higher possible upside, equities analysts clearly believe CG Oncology is more favorable than its rivals.

Valuation & Earnings

This table compares CG Oncology and its rivals gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
CG Oncology	$684,000.00	-$48.61 million	-15.66
CG Oncology Competitors	$574.62 million	-$70.96 million	0.08

CG Oncology’s rivals have higher revenue, but lower earnings than CG Oncology. CG Oncology is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Institutional & Insider Ownership

26.6% of CG Oncology shares are owned by institutional investors. Comparatively, 50.4% of shares of all “Biological products, except diagnostic” companies are owned by institutional investors. 15.7% of shares of all “Biological products, except diagnostic” companies are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Volatility and Risk

CG Oncology has a beta of 1.6, indicating that its share price is 60% more volatile than the S&P 500. Comparatively, CG Oncology’s rivals have a beta of -3.86, indicating that their average share price is 486% less volatile than the S&P 500.

Summary

CG Oncology beats its rivals on 8 of the 13 factors compared.

About CG Oncology

CG Oncology, Inc., an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients. It also develops PIVOT-006, a cretostimogene monotherapy for intermediate-risk NMIBC following transurethral resection of the bladder tumor; and CORE-008 for treating patients with high-risk NMIBC, including BCG-exposed and BCG-naïve NMIBC patients. CG Oncology, Inc. was formerly known as Cold Genesys, Inc. and changed its name to CG Oncology, Inc. in June 2020. The company was founded in 2010 and is based in Irvine, California.